Blood and AI pathology to guide treatment in resectable lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study checks whether special blood testing plus computer-based review of tumor slides can help plan care for lung squamous cell cancer that can be removed by surgery. It looks at patients who have not had prior cancer treatment and who meet specific stage and health criteria.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have lung squamous cell cancer confirmed by pathology or cytology
- You’re age 18 to 75, and you can and agree to sign consent
- Your lung cancer is stage II to IIIb and considered resectable or possibly resectable
- You have not had any prior cancer treatment for this tumor
- You can provide enough blood/tissue samples for the study tests
- Your health status score is 0 to 1 (you’re generally able to do normal activities)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at a new blood test to predict how well standard-of-care chemotherapy plus immunotherapy works for people with advanced non-small cell lung cancer. It aims to personalize treatment by identifying patients who may benefit most, potentially improving outcomes and reducing unnecessary side effects.
This study is testing whether a simple blood test (called ctDNA-MRD) can help guide treatment for people with advanced lung cancer that has not spread far. You would receive chemotherapy plus immunotherapy before surgery, and the blood test may help doctors understand how well the treatment is working.
This study uses a blood test called ctDNA to look for leftover lung cancer after surgery. Based on that result, the trial will help decide which treatment approach is best for you and may catch cancer returning earlier.
This study looks at how tumor and blood biomarker results can guide treatment for people with non-small cell lung cancer (NSCLC). Depending on the cancer stage, it may follow standard-of-care treatment plans around surgery or first-line immunotherapy.
This trial uses advanced gene sequencing technology on blood and tumor tissue samples from people with non-small cell lung cancer. The goal is to see if this testing can help doctors better predict which treatments will work and detect if the cancer comes back early.
This study uses a special blood test to look for tiny traces of lung cancer after surgery. It aims to find “minimal residual disease,” meaning cancer cells that may still be hiding after your tumor is removed.
Hear when a new Lung Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.